GlassScriptPhysician profile
Bhadresh B Shah
NPI 1770555682
$6,114.84
in general payments reported to CMS, 2019-2025
31 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $907 · 2021: $2,737 · 2022: $255 · 2023: $570 · 2024: $187 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,812.15 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,772.36 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $964.34 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Mylan Specialty L.P. | $722.00 | 2020 | |
| Insmed, INC. | $390.02 | 2021-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $294.80 | 2024-2025 | Aralast, Glassia |
| Inogen, INC. | $132.92 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Eisai INC. | $109.63 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $72.96 | 2023-2025 | Dupixent |
| Genzyme Corporation | $69.86 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $68.42 | 2019 | |
| Pfizer INC. | $56.24 | 2022-2024 | |
| Viatris Specialty LLC | $47.31 | 2025 | Yupelri |
| Sanofi Pasteur INC. | $41.47 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $41.13 | 2021 | |
| Amgen INC. | $34.00 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $27.06 | 2019 | |
| Hikma Pharmaceuticals USA | $25.00 | 2023 | Ryaltris |
| Lilly USA, LLC | $24.41 | 2025 | Zepbound, Mounjaro |
| 3b Medical, INC. | $24.38 | 2025 | Luna |
| Genentech USA, INC. | $20.36 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.11 | 2024 | Acthar |
| Vanda Pharmaceuticals INC. | $19.53 | 2019 | |
| Pulmonx Corporation | $19.09 | 2019 | |
| Optinose US, INC. | $18.31 | 2021 | |
| Circassia INC. | $17.65 | 2019 | |
| Azurity Pharmaceuticals, INC. | $16.88 | 2025 | Alvesco |
| Tactile Systems Technology INC | $16.86 | 2023 | Entre Plus, Flexitouch Plus |
| Paratek Pharmaceuticals, INC. | $16.36 | 2021 | |
| Shionogi INC | $13.20 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.18 | 2024 | Quviviq |
| United Therapeutics Corporation | $5.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhadresh Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.